Secured Convertible Facility Agreement Sample Contracts

SECURED CONVERTIBLE FACILITY AGREEMENT
Secured Convertible Facility Agreement • August 14th, 2020 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • England and Wales

First Amendment to Secured Convertible Facility Agreement (this “Amendment”) by and between AgeX Therapeutics Inc., a Delaware corporation (“Borrower”) and Juvenescence Limited, a British Virgin Islands company (“Lender”) is effective as of July 21, 2020 (“Effective Date”).

AutoNDA by SimpleDocs
SECURED CONVERTIBLE FACILITY AGREEMENT
Secured Convertible Facility Agreement • March 15th, 2023 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • England and Wales

This Third Amendment to Secured Convertible Facility Agreement (this “Amendment”) by and between AgeX Therapeutics Inc., a Delaware corporation (“Borrower”) and Juvenescence Limited, a company incorporated in the Isle of Man with company number 018008V and its registered office at 1st Floor Viking House, St Pauls Square, Ramsey, Isle of Man, IM8 1GB (“Lender”) is effective as of March 10, 2023 (“Effective Date”).

AGEX THERAPEUTICS INC. (as Borrower) - and - JUVENESCENCE LIMITED (as Lender) - and – RECYTE THERAPEUTICS INC. (as Guarantor) - and – REVERSE BIOENGINEERING, INC. (as Guarantor) SECURED CONVERTIBLE FACILITY AGREEMENT
Secured Convertible Facility Agreement • March 30th, 2020 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • England and Wales

This Agreement shall set forth the terms and conditions upon which the Lender has agreed to provide a secured convertible facility to the Borrower, not exceeding the aggregate principal amount of up to US$8,000,000 (eight million dollars) on the terms and conditions set out in this Agreement.

SECOND AMENDMENT TO SECURED CONVERTIBLE FACILITY AGREEMENT
Secured Convertible Facility Agreement • November 16th, 2020 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • England and Wales

This Second Amendment to Secured Convertible Facility Agreement (this “Amendment”) by and between AgeX Therapeutics Inc., a Delaware corporation (“Borrower”) and Juvenescence Limited, an Isle of Man company (“Lender”) is effective as of November 12th, 2020 (“Effective Date”).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!